argenx SE | OpenBizGraph

Company name

argenx SE

Website

Start date

End date

Ticker

Listed market

NASDAQ

Country

United States of America

Business activities

Develops therapies for autoimmune diseases including VYVGART for myasthenia gravis.

Head office

Laarderhoogtweg 25, Amsterdam, 1101 EB, Netherlands

Chief executive

Karen Massey

Employees (non-consolidated)

Employees (consolidated)

Related companies

Company name

Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder

Relationship graph

News

+ Loaded when opened

Data sources

News pages

Own domain

✅

Last updated

2026-09-21 18:15 (Model: )